Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to 0.52%.

  • Voyager Therapeutics' Return on Capital Employed fell 5400.0% to 0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year decrease of 5400.0%. This contributed to the annual value of 0.26% for FY2024, which is 9000.0% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Return on Capital Employed is 0.52%, which was down 5400.0% from 0.42% recorded in Q2 2025.
  • In the past 5 years, Voyager Therapeutics' Return on Capital Employed ranged from a high of 0.47% in Q4 2023 and a low of 0.65% during Q1 2022
  • Moreover, its 5-year median value for Return on Capital Employed was 0.18% (2022), whereas its average is 0.16%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first tumbled by -7600bps in 2021, then skyrocketed by 10600bps in 2023.
  • Over the past 5 years, Voyager Therapeutics' Return on Capital Employed (Quarter) stood at 0.53% in 2021, then grew by 3bps to 0.52% in 2022, then surged by 191bps to 0.47% in 2023, then plummeted by -149bps to 0.23% in 2024, then tumbled by -125bps to 0.52% in 2025.
  • Its last three reported values are 0.52% in Q3 2025, 0.42% for Q2 2025, and 0.31% during Q1 2025.